ClinicalTrials.Veeva

Menu

Special Drug Use Investigation for LAMICTAL® (Long Term)

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status

Completed

Conditions

Epilepsy

Treatments

Drug: Lamotrigine tablets

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

The objectives of this post-marketing surveillance (PMS) are to grasp the actual use of lamotrigine tablets to collect safety information in the long-term use according to seizure type and concomitant antiepileptic drug (AED), and to confirm its efficacy.

Enrollment

850 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome
  • Subjects who are treated with lamotrigine tablets

Exclusion criteria

  • None

Trial design

850 participants in 1 patient group

Subjects prescribed lamotrigine tablets
Description:
Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
Treatment:
Drug: Lamotrigine tablets

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems